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1. Introduction 
G protein-coupled receptors (GPCRs) are the largest superfamily of transmembrane proteins 
and due to their ubiquitous expression and vast array of functions they present attractive 
targets for the treatment of a wide number of diseases and disorders. Accordingly, they 
represent up to 30% of targets of current therapeutics (Overington et al., 2006). Despite the 
capacity of GPCRs to modulate many (patho-)physiological functions there is a high 
attrition rate with regard to new compounds entering clinical trials. There are many reasons 
for the number of failed drug-like compounds such as non-specificity, unfavourable 
pharmacokinetic profile and lack of clinical efficacy. In this regard, molecules targeting 
neurotransmitter receptors in the CNS traditionally have poor side-effect profiles due to the 
high concentrations required to pass the blood-brain barrier. There remain many specific 
challenges in drug discovery such as promiscuous GPCR-effector coupling; differential cell- 
and tissue-specific effects; ligand-induced changes in receptor trafficking; and protein-
protein interactions and receptor oligomerisation (Galandrin et al., 2007; Hanyaloglu and 
von Zastrow, 2008; Kniazeff et al., 2011; Wettschureck and Offermanns, 2005).  
GPCRs are divided into three main classes (A-C) based on structural homology; however all 
GPCRs possess a 7-alpha-helical transmembrane-spanning (7TM) domain, which facilitates 
the transduction of extracellular signals into intracellular responses. GPCRs recognise a 
myriad of different stimuli from photons, amino acids and biogenic amines to large peptides 
and proteins. Class A (rhodopsin-like) GPCRs are among the best characterised and consist 
of a relatively short N-terminal domain, a 7TM domain connected by extracellular and 
intracellular loops, and an intracellular C-terminal domain (Fredriksson et al., 2003). Class B 
(secretin-like) GPCRs have comparatively long N-terminal domains with similar 7TM and 
C-terminal topography as Class A receptors. By far and away, Class C (glutamate-like) 
GPCRs have the most distinct topography compared the other GPCRs; they possess large, 
structured N-terminal domains, which form a venus-fly trap-like structure known as the 
venus-fly trap (VFT) domain. The VFT domain is often (with exceptions) connected to the 
7TM domain via a cysteine-rich domain, and further to this the C-terminal domain is often 
comparatively longer than those of Class A GPCRs. Structurally, all GPCRs are similar in 
their 7TM domains, yet the activation mechanisms, at least by the endogenous ligand varies 
www.intechopen.com
 Pharmacology 
 
4 
greatly across the classes. The orthosteric (endogenous ligand) binding site in Class A 
GPCRs lies in the 7TM helical bundle (with exceptions, e.g. CXCR4 chemokine receptor and 
relaxin family receptors (Allen et al., 2007; Sudo et al., 2003)); class B receptor ligands tend to 
bind in the large N-terminal domain and have been postulated to possess a bimodal 
receptor activation mechanism, whereby after the ligand binding event the ligand-N-
terminal complex inserts into the 7TM helical bundle to elicit receptor activation (Hoare, 
2005); class C receptor orthosteric ligands bind in the VFT domain and, through a series of 
conformational changes, are able to induce receptor activation via the 7TM domain (Pin et 
al., 2004)(Figure 1). 
 
Fig. 1. Canonical orthosteric ligand-binding domains of the three classes of GPCRs. 
Highlighted in yellow are the typical binding regions of orthosteric ligands, in addition to 
the general architecture of the three major classes of GPCRs. 
One large hindrance to drug discovery is the high degree of protein sequence and structural 
conservation between orthosteric sites of receptors of the same family, increasing the 
difficulty to specifically and selectively target a single receptor subtype. However, by their 
very nature GPCRs are highly dynamic proteins that are able to adopt a spectrum of 
conformational arrangements and it is this characteristic that allows GPCRs to be modulated 
by, not only a range of orthosteric ligands, but also ligands that bind in a topographically 
distinct region to the orthosteric binding pocket. These ligands are known as allosteric 
ligands and are able to modulate the affinity and/or efficacy of the orthosteric ligand, and 
indeed, possess their own efficacy in the absence of orthosteric ligand (Christopoulos and 
Kenakin, 2002; Conn et al., 2009a). This phenomenon presents a unique opportunity to 
exploit GPCRs as drug targets through offering novel and often less-conserved ligand 
binding sites across receptor subtypes. 
Despite the best-characterised coupling partners of GPCRs being heterotrimeric G 
proteins, they are also well known to couple to a host of other intracellular proteins (e.g. 
arrestins and small G proteins (Burridge and Wennerberg, 2004; Lefkowitz, 1998)), thus 
adding an extra degree of complexity to the pluri-dimensional response of ligand-GPCR 
interactions. Furthermore, promiscuous coupling has been shown, in some cases, to be a 
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concentration- and/or oligomerisation-dependent event (Sato et al., 2007; Scholten et al., 
2011; Urizar et al., 2011). 
Taken together, the ligand-receptor-effector combinations, receptor oligomerisation and 
allosteric modulation of GPCRs furnish a mode of fine-tuning functional outputs and 
potentially, therefore, clinical outcomes.  
This chapter will focus on two major receptor types of Class C GPCRs, the metabotropic 
glutamate and metabotropic -amino-butyric acid (GABA) receptors, which are the GPCRs 
of the major excitatory and inhibitory neurotransmitters in the adult brain, respectively. 
These receptors represent major targets for many CNS disorders such as schizophrenia, 
Parkinson’s disease, Alzheimer’s disease, epilepsy and diseases of addiction (Conn et al., 
2009a; Tyacke et al., 2010). 
2. Metabotropic glutamate receptors 
2.1 Phylogeny and structure/function of mGlu receptors 
Metabotropic glutamate (mGlu) receptors are widely expressed in the CNS and are 
activated by the excitatory neurotransmitter, glutamate. These receptors play a vital role in 
the regulation on neuronal excitability and synaptic transmission (Conn and Pin, 1997). 
Consequently, these receptors are valuable targets for treating neurological disorders such 
as schizophrenia, Parkinson’s disease and neuropathic pain, either by correcting 
neurological imbalances in non-glutamatergic systems or through treating disregulation of 
glutamatergic signalling.  
The members of the mGlu receptor family are obligate dimers and long thought of as 
obligate homodimers, but have recently been demonstrated to selectively form heterodimers 
amongst other mGluR subtypes in HEK cells (Doumazane et al., 2011). This propensity may 
be of utility in texturing the glutamatergic response across diverse brain regions. mGlu 
receptors consist of 8 subtypes that are divided into three subgroups (I-III) based on 
sequence homology, function and pharmacological profile (Pin and Acher, 2002). Group I 
mGluRs (mGlu1 and mGlu1) are Gq/11-coupled thereby signalling through the phospholipase 
C-IP3-Ca2+ axis; whereas Group II (mGlu2 and mGlu3) and Group III (mGlu4, mGlu6, mGlu7 
and mGlu8) signal through inhibitory G proteins (Gi/o), which most likely serve as 
intermediaries between the receptor and ligand-gated ion channels, such as voltage-
operated potassium channels (Kv2 channels) and voltage-operated calcium channels (Cav2 
channels) (Doupnik, 2008; Herlitze et al., 1996; Peleg et al., 2002).  
In drug discovery the understanding of the molecular mechanisms of ligand binding and 
receptor activation are paramount in order to investigate novel and improved methods for 
targeting these receptors therapeutically. In this regard, it is important to determine the 
overall receptor activation event by breaking it down into its fundamental component. 
Furthermore, to gather information about mGlu receptors, we must also use information 
gained from studies of other Class C GPCRs to form a global conformational image. Ligand 
binding in a VFT structure has been described with the periplasmic binding protein, which 
appears to be similar in class C receptors (O'Hara et al., 1993). The VFT remains in a state of 
equilibrium between two main conformations: open (o) and closed (c), known as the resting 
state. The orthosteric ligands bind primarily to the open VFT in lobe 1 and subsequently 
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promote the closed conformation as interactions with lobe 2 stabilises this state. This 
suggests that, if agonists induce the closure of the VFT, orthosteric antagonists act to prevent 
the closure of the VFT, thereby blocking the appropriate mechanisms leading to 7TM 
activation (Bessis et al., 2000; Bessis et al., 2002; Kunishima et al., 2000; Tsuchiya et al., 2002). 
For a number of years, the question on how ligand binding in the VFT results in 7TM 
activation remained to be elucidated. The breakthrough came from the first crystal structures 
of a class C VFT dimer, from the mGlu1 receptor, crystallised in the presence and absence of 
glutamate (Kunishima et al., 2000). These structures confirmed the overall structure of the 
domain and, perhaps more importantly, the agonist binding mode in a single VFT domain. It 
also revealed large, structural rearrangements of the VFT dimer resulting in a change of the 
relative orientation of the two protomers. A general mechanism for VFT dimer conformational 
changes was proposed by the authors: two orientations of the VFT dimer exist and are in 
equilibrium: a resting (R) and an active (A) orientation. In the R orientation, the VFTs interact 
via lobe-I only, leaving the lobes-II separate from each other. In the A orientation, there is a 
reorganization of the VFTs relative orientation such that they also interact via each lobe-II. This 
large reorientation from R to A was proposed to induce the conformational changes required 
for 7TM activation. Resting and active designations were given to the different orientations as 
glutamate was proposed to stabilize the A form. The active and inactive property of the A and 
R orientations are further supported by mGlu1 structures obtained in the presence of an 
antagonist (MCPG) or in the presence of a potentiator (Gd3+) in which the dimer orientation is 
R and A, respectively (Tsuchiya et al., 2002). 
When considering the various conformations for the VFT and the VFT dimer, there are a 
total of six theoretical conformations that are possible: Roo, Rco and Rcc and Aoo, Aco and 
Acc, where A and R are indicative for the VFT dimer orientation and c and o for the VFT 
conformation. It is assumed that agonist binding to at least one of the VFT stabilizes the c 
form, which is the driving force leading to the VFT dimer reorientation from R to A. In 
agreement, only Roo, Rco, Aco and Acc are likely to exist. However, new crystal structures 
of the isolated VFT dimer in the ‘forbidden’ conformation Rcc (Muto et al., 2007) and Aoo 
(PDB accession number, 3KS9) were recently deposited in the protein data bank (PDB). In 
particular, the Aoo conformation appears to be highly unlikely to occur within a dynamic 
equilibrium as many residues of the same polarity from lobe 2 would be in close proximity 
to one another, so much so that this would likely destabilise this conformation through the 
repulsive forces exerted within lobe 2 (Tsuchiya et al., 2002). Whilst explanations for these 
surprising observations have not been provided, the absence of 7TM may have alleviated 
some conformational constraints that may otherwise be exerted on the VFT from the 7TM, 
acting as a structural tether that inhibits certain conformations.  
A question arising upon closer analysis of the crystal structure is the number of agonists 
needed to activate a class C GPCR dimer. When considering the reorientation of the VFT 
from R to A as the sole mechanism responsible for 7TM activation, one may wonder 
whether there is a functional difference between Aco and Acc conformation. In other words, 
what would be the difference in binding one or two agonists? It was shown that in class C 
heterodimers a single subunit was responsible in binding the endogenous ligand (GABAB1 
in GABAB receptor and T1R1 or T1R2 in the taste receptors)(Kniazeff et al., 2002; Nelson et 
al., 2001). This suggests that a single agonist molecule is sufficient to fully activate 
heterodimeric receptors in these cases. 
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As we have described above, an allosteric modulator binding in the 7TM affects both the G 
protein activation and agonist affinity for the VFT. Together with the fact that a 
conformational change in the VFT dimer activates the 7TM, this indicates that VFT and 7TM 
converse in both ways. The question that remains is how the stimulus is transduced through 
the VFT region to the 7TM domain?  
In most of class C GPCRs, VFT and 7TM are connected with the CRD. The CRD is an 80 
residues long domain containing 9 cysteines. This domain is present in mGlu, CaS, GPRC6A 
and T1R receptors, but not in GABAB receptors. The structure of this domain has been 
solved for mGlu3 (Muto et al., 2007), and this domain appears to be a rigid 40Å long 
structure, which is most likely to form a physical gearing system between the VFT and 7TM 
domains. In agreement with these physical findings, both deletion of the CRD in mGlu or 
CaS receptors and mutations of T1R3 CRD abolish the agonist-induced receptor activation 
(Hu et al., 2000; Jiang et al., 2004). Furthermore, we have shown that the VFT and CRD 
domains in mGlu2 are linked by a disulphide bridge between a cysteine at the bottom of the 
VFT and the only cysteine that is not engaged in intradomain disulphide bond within the 
CRD (Rondard et al., 2006). Rondard et al., had shown that the mutation of the residues 
involved in this interaction abolished agonist-mediated activation of the receptor. This 
supports the idea of a central role for the CRD in the transduction of the conformational 
changes from the VFT dimer to the 7TM in these receptors. 
The exact mechanisms of 7TM activation Class C and indeed, mGlu receptors remain to be 
solved. This notwithstanding, there are approaches that can be employed in an attempt to 
determine the molecular mechanisms involved in the conformational changes that the 7TM 
domains undergoes upon activation. One of these approaches is entails the use of both 
positive and negative allosteric modulators. The first allosteric modulators of class C GPCRs 
to be described were found to be non-competitive antagonists or inverse agonists (Carroll et 
al., 2001; Litschig et al., 1999; Pagano et al., 2000). Other compounds have been described that 
potentiated the effect of the agonists (increased affinity and efficacy) (Felts et al., 2010; 
Hammond et al., 2010; Urwyler et al., 2001). These molecules are structurally distinct from the 
orthosteric agonists and antagonists, as reflected in their binding within the 7TM, in a binding 
region that is reminiscent of the orthosteric binding pocket in Class A receptors (Brauner-
Osborne et al., 2007; Goudet et al., 2004). So far, no endogenous PAM or NAM binding in the 
7TM pocket has been described. Selective pressure in the evolution of a site/pocket is often 
indicative of a biological function, but there is no conserved pocket located within the 7TM 
domain of mGluRs, making it less likely that there is an endogenous allosteric ligand that acts 
in that region. The absence of conservation allowed the discovery of molecules specific for a 
single subtype of mGlu receptor, as opposed to a ligand acting at the well conserved 
orthosteric binding site. If both PAM and NAM act at the 7TM, then their opposite effects are 
likely due to differences in the residues that the ligands are in contact with in the 7TM. 
Specifically, several studies indicate that PAM and NAM bind to overlapping but not identical 
sites (Miedlich et al., 2004; Petrel et al., 2004). Some of these interaction networks should 
stabilize the active conformation of the 7TM, whilst some others should lock the receptor in its 
inactive conformation. However, it was shown that structurally different molecules bind 
essentially at the same position in the 7TM, only the precise identity of the residues contacting 
the molecule may differ. It appears that the position of PAM/NAM binding site is largely 
conserved in the whole family and includes residues from TM3, 5, 6 and 7 (Hu et al., 2000; 
Miedlich et al., 2004; Pagano et al., 2000). However, in some cases, two distinct sites have been 
www.intechopen.com
 Pharmacology 
 
8 
identified for PAMs, as exemplified at mGlu5 (Chen et al., 2008). See Figure 2 for a schematic 
overview of mGlu receptor architecture and binding domains. 
 
Fig. 2. Architecture, binding domains and dimerisation states of mGlu and GABAB receptors.  
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2.2 Protein-protein interactions of mGlu receptors 
Studying molecular mechanisms and pharmacology of GPCRs in heterologous cells systems 
can be exceptionally useful due to the eradication of confounding factors such as multiple 
receptor subtypes; in addition the capacity to modulate receptor expression and function of 
specific signalling pathways with relative ease. However, these systems are rarely indicative 
of native systems and it needs to be recognised that various GPCR interactions exist in vivo 
that do not exist in heterologous cell systems for a myriad of reasons. One such interaction is 
that of protein-protein interactions, whereby the physical or functional interaction of a 
number of proteins can greatly alter its behaviour. An example of this occurrence is a 
fundamental component of some Class C GPCR pharmacology, such that receptor activity-
modifying proteins (RAMPs) modulate the pharmacology of receptors such as the calcitonin 
and calcitonin receptor-like receptor (Sexton et al., 2006). mGlu receptors are also a family 
that are capable of interacting with non-mGluR proteins to form complexes. 
2.2.1 mGlu1–A1 receptors 
In cortical neurons, the simultaneous activation of adenosine A1 and mGlu1 receptors has been 
shown to synergistically decrease the neuronal toxicity due to application of NMDA (Ciruela 
et al., 2001). In astrocytes or in co-transfected HEK293 cells, activation of A1 receptors elicits an 
increased mGlu1 response via Gi/o proteins (Ciruela et al., 2001; Toms and Roberts, 1999). That 
effect could be indicative of cross-talk and priming of the intracellular Ca2+ response; however, 
Hirono et al. (2001) did not observe any potentiation of the mGlu1 response upon co-activation 
of the A1 receptor in in cerebellar Purkinje cells, supporting the hypothesis of cooperativity 
(physical or otherwise) rather than cross-talk of the signalling pathways. Although both 
receptors are co-localized and coimmunoprecipitated from neurons and transfected HEK293 
cells, the existence and the requirement of a direct physical interaction is yet to be clearly 
established (Ciruela et al., 2001). 
2.2.2 mGlu5–A2A–D2 receptors  
The mGlu5, adenosine A2A and dopamine D2 receptors are highly expressed in the striatum. 
These receptors have been proposed to play vital roles in the dysregulation of the motor 
coordination observed in the Parkinson's disease. Indeed, antagonists of both mGlu5 and 
A2A display anti-parkinsonian effects, while the dopamine D2 receptor is the target of L-
DOPA, which is used to treat parkinsonian symptoms. It has been suggested that these three 
receptors may act in concert in pairs or as a triplet via signalling cross-talk or otherwise, to 
influence the striatal function in motor coordination (Agnati et al., 2003; Cabello et al., 2009). 
Indeed, this cross-regulation was observed in vivo, where mGlu5 antagonist-induced motor 
effects were augmented by A2A receptor antagonists; and conversely these effects were 
diminished in A2A-D2 receptor double knock-out mice (Kachroo et al., 2005). The exact 
molecular mechanisms of the cross-regulation are not well understood, but DARPP-32 
(dopamine- and cAMP-regulated neuronal phosphoprotein) may play a pivotal role. 
Adenosine A2A receptors have been show to increase DARP-32 phosphorylation via the Gs 
signaling axis, whilst D2 receptors counteract this effect via the Gi/o pathway (Agnati et al., 
2003); Furthermore, the co-activation of adenosine A2A and dopamine D2 receptors 
synergistically potentiated DARPP-32 phosphorylation ex vivo studies in striatum tissues. 
Notwithstanding, the regulation of intracellular Ca2+ and cAMP signals underpins other 
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signalling interactions between these receptors (Ferre et al., 2002). Not only may this 
phenomenon be due to signalling cross talk amongst these receptors, but may be a result of 
physical interactions and allosteric regulation across heteromers. It A2A–D2 hetero-oligomers 
are mediated by electrostatic interactions between a basic-rich motif in the third intracellular 
loop of the D2 receptor and an acidic/serine residue-containing motif in the C-terminus of 
the adenosine A2A receptor (Azdad et al., 2009; Ciruela et al., 2004; Ferre et al., 2007). 
Additionally, are postulated to not only be co-expressed, but also to form hetero-oligomers 
in striatal neurons and in heterologous cells systems (Ferre et al., 2002). Recently, Cabello et 
al. (2009) demonstrated that mGlu5, dopamine D2 and adenosines A2A receptors are localised 
within the same dendritic spines in glutamatergic striatal synapses, which led them to 
hypothesise that there may be hetero-oligomeric triplets of A2A, mGlu5 and D2 receptors; this 
association was then investigated through the employment of various fluorescence 
techniques. Their data supported the formation of heterooligomers containing all three 
receptors and thus allosterically interacting with one another to influence either efficacy or 
affinity or both. It is noteworthy that additional cross-regulation between A2A and mGlu5 
receptors has been reported in hippocampal neurons, where the inhibition of A2A receptors 
decreased the mGlu5-mediated potentiation of NMDA receptor responses (Tebano et al., 
2006). However, the molecular mechanisms involved are yet to be elucidated. 
2.2.3 mGlu2–5-HT2A receptors 
One of the best-characterized receptor complex involving a Class C GPCR is the complex 
between mGlu2 and the serotonin 5-HT2A receptor. It is well documented that these 
receptors are both targeted by antipsychotic drugs such as 5-HT2A receptor inverse agonists 
and mGlu2 receptor agonists and PAMs (Benneyworth et al., 2008; Benneyworth et al., 2007). 
Furthermore, 5HT2A receptors are the target of hallucinogenic substances, for example LSD 
and psilocybin, which induce hallucinogenic episodes that are thought to be similar to some 
of the symptoms in schizophrenics (Aghajanian and Marek, 1999). Indeed, non-
hallucinogenic 5HT2A agonists (5-HT included) activate the Gq signalling axis, whilst 
hallucinogenic compounds are proposed to additionally activate Gi/o and Src tyrosine 
kinase pathways, in cortical neurons (Gonzalez-Maeso et al., 2007; Gonzalez-Maeso et al., 
2003). Activation of mGlu2 receptors in the prefrontal cortex by the mGlu2 PAM, biphenyl-
indanone A (BINA), abrogated the hallucinogenic effects of compounds such as (-)2,5-
dimethoxy-4-bromoamphetamine, [(-)DOB] (Benneyworth et al., 2007); suggesting 
functional antagonism between mGlu2 and 5HT2A receptors in prefrontal cortex, an 
interaction that is possibly altered in schizophrenics (Gonzalez-Maeso et al., 2007). In fact, 
co-expression of both receptors revealed that the hallucinogen-induced Gi coupling of 5-
HT2A is ameliorated by mGlu2 in basal conditions, but abolished when mGlu2 is activated. 
The mechanism of this complex cross-talk remains to be fully unraveled, but it has been 
proposed to be the result of mGlu2–5-HT2A receptor oligomerisation. In cortical neurons, 
these receptors co-localise and co-immunoprecipitate (Gonzalez-Maeso et al., 2008). Indeed, 
biophysical approaches have been employed to demonstrate that these GPCRs are in fact in 
close enough proximity to be compatible with a physical association (Gonzalez-Maeso et al., 
2008). Moreover, by adopting a chimeric approach between mGlu2 and mGlu3 (TM4 and 
TM5 substitution), the authors were able to demonstrate that mGlu3 receptors with 
substituted TM domains were able to oligomerise with the 5-HT2A receptor, further to 
exhibiting functional cross-talk (Gonzalez-Maeso et al., 2008). This supports the potential 
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relationship between receptor oligomerisation and functional cross-talk. The study of the 
precise mechanism of this phenomenon is still ongoing, and can perhaps furnish novel 
approaches for targeting these receptors for the treatment of schizophrenia and other 
neuronal disorders. 
2.2.4 mGlu5-NMDA receptors 
Another important interaction that further implicates the role of the glutamatergic system in 
schizophrenia is the interaction of the N-methly-D-aspartate (NMDA) receptor and mGlu5. 
This GPCR-ion channel interaction has been relatively well characterised from a functional 
stand point, but the molecular mechanisms of the interaction are only beginning to be 
unfolded.  
Indeed, in hippocampal neurons, mGlu5a co-localises with NMDA receptors, which 
mediates a slow excitatory postsynaptic current (Collingridge et al., 1983; Oliet et al., 1997). 
The activation of mGlu5 receptors enhances the NMDA-evoked responses in different 
regions of the brain, such as the hippocampus, the striatum, the cortex, or the spinal cord 
(Aniksztejn et al., 1992; Harvey and Collingridge, 1993). Recently, Perroy et al., (2008) have 
shown that both receptors, indeed, interact via the C-terminal domain of mGlu5a. Through 
use of the bioluminescence resonance energy transfer (BRET) approach, they demonstrated 
that a significant and specific BRET signal can be measured between the two receptors, and 
moreover that this signal was transiently increased by activation of either the mGlu5a 
receptor or the NMDA receptor; this suggests an allosteric interaction and ligand-dependent 
conformational rearrangement of the opposite protomer in the hetero-oligomer. 
Interestingly however, when co-expressed, the functional response of the either receptor 
was reduced, compared to the response when either receptor was expressed in isolation. 
Thus suggesting a reciprocal and constitutive suppression of the signalling between NMDA 
and mGlu5a receptors, which was suggested to be independent of the G protein coupling of 
mGlu5a. The inhibitory reciprocal effect was dependent on the physical interaction between 
these receptors, given that the inhibition was abolished upon suppression of the C-terminal 
domain involved in receptor hetero-oligomerisation (Perroy et al., 2008).  
2.3 Localisation and physiological function 
Group I mGlu receptors (mGlu1 and mGlu5) are extensively expressed throughout neurons 
in the CNS and, in addition, mGlu5 is expressed in glial cells. mGlu1 is most abundantly 
expressed in Purkinje cells of the cerebellar cortex and in the olfactory bulb, in addition to 
strong expression in the hippocampus, substantia nigra and globus pallidus (Baude et al., 
1993; Martin et al., 1992); and mGlu5 is greatly expressed in corticolimbic regions, such as 
the striatum, hippocampus and cerebral cortex (Ferraguti and Shigemoto, 2006). For 
example in the hippocampus, mGlu1 has been demonstrated to be involved in synaptic 
transmission and plasticity, in addition to neuronal excitability (Bortolotto et al., 1999), 
whilst in both mGlu1 and mGlu5 are required for the induction of long-term depression 
(LTD) in corticostriatal synapses (Sung et al., 2001). Through the use of knockout (KO) mice 
the putative function of mGluRs can be elucidated and, indeed, mGlu1 and mGlu5 KO mice 
have been studied. In mGlu1 KO animals is a marked deficits in long-term potentiation 
(LTP) in hippocampal slices and in context-dependent fear conditioning task (Aiba et al., 
1994a); suggesting reduced hippocampal-mediated learning and memory. Furthermore, 
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these mice are also cerebellar-LTD deficient, suggesting that mGlu1 receptors are important 
for LTD induction in the cerebellum and subsequently motor learning, as demonstrated by 
the ataxic gait of the mGlu1 KO mice (Aiba et al., 1994b). Recently, mice have been generated 
whereby the mGlu5 gene can be selectively disrupted in the central nucleus of the amygdala; 
these mice exhibited a lack of mechanical hypersensitivity induced by peripheral 
inflammation (Kolber et al., 2010), strongly suggesting a role of mGlu5 in the regulation of 
inflammatory pain transmission. Both mGlu1 and mGlu5 KO mice exhibit deficiencies in 
prepulse inhibition of the startle reflex, which is an indicator of sensorimotor gating that is 
impaired in schizophrenic patients, a trait that can be reversed through treatment with 
antipsychotics (Brody et al., 2003; Brody et al., 2004). 
mGlu2 and mGlu3 (Group II) are widely expressed in the CNS, of which mGlu2 is more 
limited in expression compared to mGlu3. mGlu2 expression has been observed in Golgi 
cells of the cerebellar cortex and in mitral cells of the accessory olfactory bulb (Ohishi et al., 
1998; Ohishi et al., 1994). mGlu3 receptors have been observed in the olfactory tubercle, 
neocortex, limbic cortex, and is also present in Golgi cells of the cerebellar cortex (Tamaru et 
al., 2001). Similar to Group I mGlu receptors, KO mice have also been generated for Group II 
mGluRs, with both mGlu2 and mGlu3 KO mice exhibiting a loss of mGlu2/3 agonist, 
LY354740-induced anxiolytic behaviour in an elevated plus maze test (Linden et al., 2005). 
Further to this, mGlu2, but not mGlu3 KO mice displayed a loss of Group II agonist-
mediated antipsychotic behaviour (Fell et al., 2008; Woolley et al., 2008), highlighting the 
role of mGlu2 in anxiety and psychotic behaviours. Interestingly, in addition to these 
functions, Group II mGlu receptors have also been demonstrated to modulate the release of 
other neurotransmitters, for example, LY354740 reduced KCl-induced [3H]-GABA release in 
rat primary cortical cultures, this effect was then reversed with the mGlu2/3 antagonist, 
LY341495 (Schaffhauser et al., 1998). 
Group III mGluRs (consisting of mGlu4, mGlu6, mGlu7 and mGlu8) are mainly expressed on 
presynaptic neurons throughout the CNS, with the exception of mGlu6, which is expressed 
postsynaptically on retinal ON bipolar cells (Nakajima et al., 1993). mGlu4 is highly 
expressed in the cerebellum and consequently, mGlu4 KO mice experience deficits in spatial 
memory (Gerlai et al., 1998) and learning of complex motor tasks (Pekhletski et al., 1996). 
mGlu6 KO display deficits in ON response to light stimulation, yet the OFF response 
remained unchanged (Masu et al., 1995), highlighting the importance of mGlu6 in synaptic 
neurotransmission in retinal ON bipolar cells. mGlu7 deficient mice display learning and 
memory deficits, in addition to exhibiting an epileptic phenotype (Bushell et al., 2002; Sansig 
et al., 2001). Both mGlu7 and mGlu8 KO animals display increase anxiety (Cryan et al., 2003; 
Duvoisin et al., 2005).   
As previously mentioned, the mGluR family of receptors are expressed widely through the 
CNS and exhibit a wide number of functions; moreover through KO studies, we can deduce 
the key roles played by each mGluR subtype and subsequently tailor our pharmacological 
armamentarium accordingly. 
2.4 Pharmacology and clinical relevance 
2.4.1 Ligands for group I mGlu receptors 
The first selective orthosteric agonist at mGlu1 and mGlu5 receptors is (S)-3,5-
dihydroxyphenylglycine, [(S)-3,5-DHPG], and this remains the case given that ligands such 
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as quisqualate and [(1S,3R)-ACPD] also bind to ionotropic glutamate and other mGluR 
subtypes, respectively (Niswender and Conn, 2010). A range of other orthosteric ligands 
have been generated, but have limited use due to their low affinity and/or potency. As 
previously discussed, mGlu receptor subtype selectivity is difficult to obtain due to the high 
degree of sequence and structural homology between subtypes.  
Therefore, one approach is to target non-canonical ligand-binding sites; from this strategy a 
major breakthrough in Group I mGlu receptor pharmacology was made, with the discovery 
of CPCCOEt, which was the first mGlu1 negative allosteric modulator (NAM)(Annoura et 
al. 1996). CPCCOEt was later discovered to bind to an allosteric domain and this highlighted 
the capacity of ligands to bind in allosteric binding modes, thereby modulating orthosteric 
ligand function (Litschig et al., 1999). Thereafter, structurally distinct NAMs for mGlu1 were 
also discovered such as BAY36-7620 and FTIDC (Carroll et al., 2001; Suzuki et al., 2007). 
mGlu5 selective NAMs were also identified of which the two flagship molecules were MPEP 
and MTEP, both providing good potency and selectivity (Anderson et al., 2002; Gasparini et 
al., 1999). 
In addition to NAMs, a wide variety of PAMs have also been identified and characterised. 
Two of these PAMs, Ro 67-4853 and Ro 01-6128 both potentiated DHPG-mediated VOCC 
inhibition responses in CA3 neurons, but did not exhibit any agonist activity of their own, 
suggesting their main characteristic is the allosteric potentiation of orthosteric ligand 
binding and/or efficacy (Knoflach et al., 2001). Interestingly, these PAMs were found to 
bind to a topographically distinct domain to the NAM binding region, when they failed to 
displace the well-characterised allosteric antagonist, R214127 (Hemstapat et al., 2006). These 
data suggest that mGlu1 possesses multiple allosteric binding sites, in addition to its 
orthosteric ligand-binding site. Similar to mGlu1, mGlu5 PAMs have also been discovered, 
such as DFB, CPPHA, CDPPB, VU29, and ADX47273, with CDPPB also having some PAM 
activity at mGlu1 (Conn et al., 2009b; Hemstapat et al., 2006). 
2.4.2 mGlu1 in anxiety and depression 
Anxiety and depression are two of the most common mental disorders, with a lifetime 
prevalence of approximately 17% and 12%, respectively (Andrade et al., 2003; Depping et 
al., 2010). It has now been well documented that mGlu1 receptors and the glutamatergic 
system represent tractable targets for treating these common disorders (Bittencourt et al., 
2004; Paul and Skolnick, 2003).  
Anxiety results from an imbalance between GABAergic and glutamatergic systems, either 
from overactive glutamatergic neurotransmission or inadequate GABAergic activity in 
hypothalamus, periaqueductal gray, hippocampus and prefrontal cortex (Engin and Treit, 
2008). It is hypothesised that the antagonism of mGlu1 receptors is capable of augmenting 
the GABAergic response, whilst concomitantly decreasing the NMDA receptor-mediated 
glutamatergic response in key brain regions involved in anxiety. It has been demonstrated 
that intraperitoneal administration of the mGlu1 antagonist, 1-aminoindan-1,5-dicarboxylic 
acid (AIDA), rats exhibited anxiolytic-like behaviours in the conflict drinking test and in 
elevated plus maze tests (Klodzinska et al., 2004). This reinforces the results seen by 
Chojnacka-Wojcik et al., (1997) where intrahippocampal injection of the Group I mGlu 
receptor antagonist, (S)-4-carboxy-3-hydroxyphenyl-glycine (S-4C3H-PG), reduced anxiety-
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like behaviours in rats. The anxiolytic actions of mGlu1 blockade were further confirmed 
through the study of the mGlu1-selective antagonist, JNJ16259685 (Steckler et al., 2005). This 
study demonstrated that treatment with JNJ16259685 alleviated the suppression of the 
licking response in a conflict drinking test, which is consistent with other well characterized 
anxiolytic drugs (Petersen and Lassen, 1981). However, JNJ16259685 treatment did not 
induce anxiolytic-type behaviour in elevated plus maze tests, the authors thus postulating 
that the effects of JNJ16259685 be context specific (Steckler et al., 2005). 
Depression is a complex disorder involving the interplay between different neurotransmitters, 
including noradrenaline, serotonin, dopamine and glutamate (Paul and Skolnick, 2003). Drugs 
for the treatment for depression are generally based on increasing the lifetime of biogenic 
amines, such as noradrenaline and serotonin, in the synaptic cleft, for example fluoxetine and 
escitalopram, which are inhibitors of serotonin- and serotonin and noradrenaline-reuptake 
transporters, respectively. Over the past decade, it has become more recognised that the 
glutamatergic system may also play a vital role in the regulation of depression, specifically 
NMDA receptors, where NMDA receptor expression was reduced in post-mortem depressive 
brains (Feyissa et al., 2009). This theory was retrospectively reinforced by evidence that 
NMDA receptor antagonists produce anti-depressant effects, whereby competitive and non-
competitive antagonists of NMDA receptors, 2-amino-7-phosphonoheptanoic acid (AP-7) and 
Dizolcipine (MK-801) emulated anti-depressant effects of gold standard anti-depressants 
(Trullas and Skolnick, 1990). Given the regulatory link between mGlu1 and NMDA receptors it 
was postulated that mGlu1 receptor antagonists or NAMs could mimic the anti-depressant 
effect of NMDA receptor inhibitors. The mGlu1 antagonist, JNJ-16567083 has been shown to be 
efficacious in despair-based animal models of depression, specifically forced swim test and tail 
suspension test (Belozertseva et al., 2007; Molina-Hernandez et al., 2008). 
2.4.3 mGlu5 and schizophrenia 
Schizophrenia is a complex multi-faceted disease that manifests itself as a host of symptoms 
such as paranoia, social withdrawal and delusions, along with a number of cognitive 
deficits. Given that there is no single causative factor, there is some difficulty in finding a 
suitable target. Current first-line treatment involves broad-spectrum biogenic amine (e.g. 
dopamine, serotonin, acetylcholine) receptor antagonists, but these to not satisfactorily treat 
the cognitive symptoms. The underlying rationale of this approach is to decrease 
dopaminergic neurotransmission in thalamocortical and limbic circuits. One potential mode 
of treating schizophrenia lies within targeting GABAergic and glutamateric interneuons in 
pivotal cortical and limbic regions, specifically, the disregulation of the disinhibition of 
glutamatergic neurotransmission (Chavez-Noriega et al., 2002; Coyle, 2006). The blockade of 
N-methly-D-aspartate (NMDA) receptors on these interneurons results in a glutamatergic 
disinhibition, which in turn leads to an overexcitability of thalamocortical neurons, which is 
mostly mediated by DL-a-amino-3-hydroxy-5-methylisoxasole-4-propionate (AMPA) 
receptors in thalamocortical synapses. Within these regions NMDA and mGlu5 receptors 
have been demonstrated to functionally and physically interact, i.e. the activation of mGlu5 
receptors increases the activity of NMDA receptors on GABAergic and glutamatergic 
neurons (Conn et al., 2009b); it is thus postulated that the activation of mGlu5 can be 
employed as a means to decrease neuronal excitability in thalamocortical regions. This 
hypothesis is reinforced through knockout studies, whereby the knockout of mGlu5 resulted 
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in NMDA-dependent cognitive and learning deficits (Lu et al., 1997). Therefore, adopting an 
mGlu5 agonist or PAM could alleviate the cognitive symptoms in schizophrenic patients; 
moreover, the use of a PAM will allow relatively specific mGlu5 in the afflicted region whilst 
maintaining the spatio-temporal regulation of other mGlu5-containing neurons. Indeed, the 
abovementioned mGlu5 PAM, CDPPB, which has a suitable potency and solubility profile 
for in vivo studies, has been demonstrated to decrease amphetamine-induced disruption of 
prepulse inhibition (PPI) startle response and locomotor activity (Kinney et al., 2005); and to 
increase hippocampal synaptic plasticity, an important feature in cognition (Ayala et al., 
2008; Conn et al., 2009b). 
2.4.4 Group II mGlu receptor pharmacology 
Group II mGlu receptors (mGlu2 and mGlu3) are generally localised presynaptically and 
negatively regulate cAMP signalling, and moreover, VOCCs. As with nearly all orthosteric 
mGlu pharmacological agents there is the underlying issue of selectivity. DCG-IV and 
LY379268 are reference Group II mGlu agonists, BINA and LY487379 are highly potent 
PAMs and the recently discovered MNI series of compounds (MNI-135, MNI-136 and MNI-
137) are potent negative allosteric modulators (Galici et al., 2006; Hemstapat et al., 2006; 
Johnson et al., 2003; Linden et al., 2005; Schweitzer et al., 2000). Despite the large array of 
pharmacological tools available for Group II mGlu receptors, there remains a paucity of 
ligands that selectively differentiate between mGlu2 and mGlu3, which is due to the high 
degree of sequence homology between the two. Of lesser therapeutic relevance, there are 
also Group II mGlu receptor antagonists, such as 2S-2-amino-2-(1S,2S-2-
carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid (LY341495) and (1R,2R,3R,5R,6R)-2-
amino-3-(3, 4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic acid 
(MGS0039), which have been suggested to have some anti-depressant and anti-obsessive-
compulsive characteristics; however they are mostly used and pharmacological tools 
(Palucha and Pilc, 2005; Shimazaki et al., 2004). Given the lack of selectivity across Group II 
mGlu receptors it is difficult to pharmacologically distinguish the roles of each receptor in 
various animal models of disease states without the use of knockout animals. 
2.4.5 Group II mGlu receptors in addiction 
Addiction is a unique disorder in that it is not only a physiological dependence, but is also a 
psychological dependence on, canonically, drugs of abuse. It is believed that mGlu2/mGlu3 
receptor ligands could be capable of treating addiction to such substances as cocaine and 
nicotine. In fact, not only is it that mGlu2/mGlu3 receptor activation is involved in recovery 
of a dysfunctional system in the corticolimbic system, but it has been shown that the 
function of Group II mGlu receptors is impaired, either by receptor downregulation or 
dampening of the G protein-mediated signalling, after acute and chronic stimulation by 
nicotine, cocaine and ethanol (Bowers et al., 2004; Kenny and Markou, 2004; Neugebauer et 
al., 2000). Indeed, mechanistically, the decrease in function is hypothesised to be due to an 
alteration in expression of the activator of G protein signalling 3 (AGS3), whereby AGS3 is 
overexpressed during withdrawal of repeated dosing of cocaine (Bowers et al., 2004). The 
authors went on to postulate that AGS3 gates expression of cocaine-induced plasticity in 
prefrontal cortex, via the regulation of G protein signalling. Furthermore, the 
downregulation of mGlu2/mGlu3 receptors has been observed during cocaine withdrawal 
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periods, specifically these receptors were downregulated in the shell and core of the nucleus 
accumbens (Ghasemzadeh et al., 2009). These alterations in expression and function in turn 
results in an impairment of long-term depression (LTD) in nucleus accumbens and 
prefrontal cortex in response to chronic morphine and cocaine exposure, respectively 
(Moussawi and Kalivas, 2010); similarly, a reduced activation of mGlu2/mGlu3  receptors 
resulted in a decrease in long-term potentiation (LTP) after self-administered cocaine 
withdrawal (Moussawi et al., 2009). Indeed, it is well documented that mGlu2/mGlu3 
function is altered in the case of substance withdrawal, however the system is regulated in a 
manner of ways. Explicitly, Group II mGlu receptors are involved in the circuitry that leads 
to reward processing and addictive behaviour. The activation of mGlu2/mGlu3 receptors 
with the orthosteric agonist, LY379268 resulted in the attenuation of the reinstatement of 
cocaine-seeking behaviour after exposure, compared to a conventional reinforcer (in this 
case, sweetened condensed milk) (Baptista et al., 2004). The authors proposed that this was a 
cocaine-specific effect and was most likely related to the mechanism of action of cocaine 
itself. Functionally, this regulation may lie in the pre-activation of mGlu2 receptors, whereby 
in mGlu2 knockout mice there was an increased release of glutamate and dopamine in 
response to cocaine, in the nucleus accumbens (Morishima et al., 2005). Whilst this does 
provide some evidence on how glutamate is involved in reward circuitry, one must  
remain circumspect on their conclusions given any compensatory mechanisms are not 
accounted for. 
2.4.6 Group III mGlu receptors and their ligands 
For many years, much of the drug discovery efforts have been directed towards Group I and 
II receptors to exploit their roles in central nervous disorders such as schizophrenia and 
neuropathic pain. However, of late, efforts have been turned to developing selective ligands 
for Group III as novel targets for disorders, for example, Parkinson’s disease. The 
prototypical Group III-selective orthosteric agonist is L-amino-4-phosphonobutyrate (L-
AP4), yet this ligand is only selective for Group III mGlu receptors, not within the group. In 
an attempt to ameliorate the affinity and potency, a series of constrained cyclic forms of 
glutamate were generated and so was created aminocyclopentane-1,3,4-tricarboxylate 
(ACPT-I), which showed mildly enhanced potency at mGlu4 and mGlu8 compared to mGlu5 
and mGlu6 (Acher et al., 1997; Schann et al., 2006). Similar to the agonists, there are only 
selective antagonists for Group III mGlu receptors, but not within the group. For example, 
there are the -methyl analogues of L-AP4 and L-SOP, specifically MAP4 and MSOP, 
respectively, with affinity in the micromolar range (Wright et al., 2000). In addition to these, 
there are the hallmark antagonists of mGlu receptors such as DCG-IV and LY341495, which 
both have reasonable affinity for Group III mGlu receptors, but also have strong affinity at 
Group I and Group II receptors, respectively; notably, DCG-IV is also a Group II mGlu 
receptor agonist (Brabet et al., 1998). Allosteric modulators that act in the 7TM domain 
Group III mGlu receptors have also been characterised, specifically N-Phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1acarboxamide (PHCCC) and cis-2-([(3,5-
Dichlorophenyl)amino]carbonyl)cyclohexanecarboxylic acid (VU0155041), which are both 
PAMs at mGlu4 (Niswender et al., 2008); 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-
isoxazolo[4,5-c]pyridine-4(5H)-one hydrochloride (MMPIP), a NAM for mGlu7 (Niswender 
et al., 2010); however there remains a relative paucity of allosteric modulators for mGlu6 and 
mGlu8.  
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One pharmacological avenue that is only beginning to be explored at Class C GPCRs is that 
of extracellular domain allosteric modulators. For the umami taste receptors, it has been 
long known that purinergic ribonucleotides, such as inosine- and guanine-monophosphate 
molecules (IMP and GMP) were potent positive allosteric modulators of the L-glutamate 
action at the umami receptor (Yamaguchi and Ninomiya, 2000). Interestingly, mutants that 
altered the effects of glutamate effect were also enhanced by IMP and GMP (Zhang et al., 
2008). By employing a chimeric approach along with mutagenesis and molecular modelling, 
sweet-umami receptors were analysed and the mode of binding and action of IMP was 
postulated; specifically, the residues lining the IMP binding pocket at the sweet-umami taste 
receptor, T1R1, were determined (Zhang et al., 2008). It was demonstrated that IMP binds to 
a novel site that is adjacent to the glutamate binding pocket, the authors thus proposed a 
model for ligand cooperativity for the mechanism of action of IMP in the T1R1 VFT. The 
binding of L-glutamate close to the hinge region of the VFT would stabilize the closed 
conformation of the domain; moreover, binding of 5' ribonucleotides to an adjacent site 
closer to the putative entrance of the VFT would further stabilize the closed conformation, 
thereby potentiating the affinity and/or efficacy of L-glutamate. At mGlu receptors, the 
glutamate-binding pocket is well conserved across the mGlu subtypes, encumbering the 
discovery selective orthosteric agonists and antagonists (Brauner-Osborne et al., 2007). 
However, recently, long alkyl chain containing derivatives of (R)-PCEP, a molecule 
discovered by virtual screening on the VFT of mGlu receptors, revealed a new binding 
pocket in mGlu4 (Selvam et al., 2010). Indeed, these compounds not only bind in the 
glutamate-binding pocket itself, but may also interact with a novel, putative binding pocket 
adjacent to the glutamate-binding site. Given this new interacting region is formed with 
residues that are less conserved across the eight mGlu subtypes, this mode of targeting 
mGlu receptors may furnish compounds with greater selectivity. One such compound may 
already exist in LSP1-2111, with its L-AP4-like moiety and a 4-hydroxy-3-methoxy-5-nitro-
phenyl moiety, it is possible that this molecule bridges across two distinct binding domains, 
in a similar fashion to bitopic ligands at muscarinic receptors (Antony et al., 2009; Valant et 
al., 2008; Valant et al., 2009). Accordingly, this ligand has superior selectivity at mGlu4 and 
mGlu6 over mGlu7 and mGlu8 (Beurrier et al., 2009). 
For an overview of chemical structures of a small range of classical orthosteric mGlu 
receptor ligands, refer to Figure 3 below. 
2.4.7 Group III mGlu receptors and Parkinson’s disease 
Parkinson’s disease is one of the most common of neurological disorders, which is largely 
characterised by its effects on motor function, such as bradykinesia and dyskinesia; further 
to other non-motor symptoms, for example pain and gastrointestinal dysfunction. 
Parkinson’s disease arises mostly due to a progressive degeneration of dopaminergic 
neurons in the substantia nigra, leading to excessive cholinergic neurotransmission in the 
striatum (Pisani et al., 2003). Subsequently, the inhibitory effect that dopamine provides in 
these circuits augments GABAergic firing in the striatopallidal pathway leading to excessive 
inhibition of GABAergic neurons in the subthalamic nucleus, in turn leading to the 
abnormal enhancement of glutamatergic neurons (Hirsch, 2000). Currently, the frontline 
treatment is levo-dopa, which compensates for the diminished dopaminergic function. 
However, the activation of presynaptic mGlu4 specifically, may result in the diminution of 
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Fig. 3. Highlighting the structural diversity of agonist and antagonists of mGlu receptors. 
increased GABAergic firing in striatopallidal projections. Indeed, compounds that have 
relatively good selectivity for mGlu4 have been demonstrated to depress the GABA-
mediated inhibitory synaptic transmission and relive motor symptoms in animal models of 
Parkinson’s disease (Beurrier et al., 2009; Valenti et al., 2003). Given that the dopaminergic 
dysfunction in the substantia nigra and inhibition of GABA signalling by mGlu4 in the 
globus pallidus are not inextricably linked there is potential that prolonged mGlu4 receptor 
activation will result in less compensatory over-activation of the dopaminergic system, 
therefore maintaining the therapeutic activity of mGlu4 targeting ligands (Nicoletti et al., 
2011).  Indeed, it has been shown that the in vivo treatment with the mGlu4 PAM, PHCCC, 
reduced dopaminergic neurodegeneration in substantia nigral projections in an MPTP-
induced Parkinsonism model (Battaglia et al., 2004; Maj et al., 2003). Along with PHCCC, a 
more recent PAM of mGlu4 has been characterised and has demonstrated anti-parkinsonian 
effects (Niswender et al., 2008). VU0155041 is an allosteric agonist and positive allosteric 
modulator with potency nearly 10-fold of that of PHCCC, moreover, VU0155041 
concentration-dependently diminished haloperidol-induced catalepsy and reversed 
reserpine-mediated akinesia in mice, with an effect that persisted longer than that of the 
reference Group III orthosteric agonist, L-AP4 (Niswender et al., 2008).   
www.intechopen.com
 Metabotropic Receptors for Glutamate and GABA 
 
19 
Despite receiving much of the attention within Group III mGlu receptors, mGlu4 is not alone 
in its involvement in Parkinson’s disease. There remains the possibility that post-synaptic 
mGlu7 and mGlu8 have some effect on the neuronal circuitry in question. The mGlu7 
allosteric agonist, N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride (AMN082) may 
inhibit the release of [3H]-D-aspartate in substantia nigral slices, suggesting that selective 
targeting of mGlu7 may yield similar results to those at mGlu4 (unpublished data; Duty, 
2010). Despite there being a large amount of doubt surrounding the therapeutic potential of 
mGlu8 for the treatment of Parkinson’s disease, where the semi-selective mGlu8 agonist was 
failed to reverse haloperidol-induced catalepsy (Lopez et al., 2007); administration of the 
mixed AMPA antagonist/mGlu8 agonist, (R,S)-3-4-DCPG, decreased amphetamine- but not 
phencyclidine-induced hyperactivity (Ossowska et al., 2004). Concomitantly, (R,S)-3-4-
DCPG actually enhanced haloperidol-induced catalepsy and induced catalepsy when 
administered alone. Taken together, and despite similar expression and function compared 
to mGlu4, does not appear to be a good candidate target for the treatment of Parkinson’s 
disease. Indeed, this scenario highlights the inherent difficulties that are encountered in the 
search for mGlu receptor subtype-selective therapeutics. 
Taken together, it seems that the most appropriate and effective methods for targeting mGlu 
receptors is via their allosteric ligand-binding site, which increases subtype selectivity and 
does not impede normal neurotransmission. Refer to Figure 4 for the chemical structures of 
some allosteric ligands for mGlu receptors. 
 
Fig. 4. Chemical structures of mGlu receptor allosteric ligands. 
2.4.8 Clinical trials for mGlu receptor ligands 
It is now well established that mGlu receptors are major targets for numerous central 
disorders and even for some in the periphery. Accordingly, there are a large number of 
clinical programs that are running at any one time (Table 1). 
Gastro-(o)esophageal reflux disease (GERD) is a chronic condition, in which the major 
symptom is the abnormal reflux of stomach contents into the oesophagus. The inhibition of 
mGlu5 is predicted to improve the tone of the cardiac sphincter, thus reducing reflux 
(Lehmann, 2008). In a recent phase II clinical study performed by Addex pharmaceuticals, 
reflux and other GERD symptoms are efficiently reduced by a NAM of mGlu5. The same 
molecule has also entered into a different phase II study targeting migraine, which also 
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yielded beneficial results. Since glutamate is the main neurotransmitter of the migraine 
circuit, then inhibition of postsynaptic mGlu5 receptors that are present in this circuit would 
decrease glutamatergic neurotransmission and hence may pose a useful approach in 
migraine therapy. However, due to liver toxicity after long-term treatment with this 
particular molecule, the study was discontinued. Fragile X syndrome is the most common 
form of inherited mental retardation. Preclinical studies indicate that fragile X phenotypes 
are linked to an overactivity of mGlu5 (Dolen et al., 2010), suggesting that antagonism of this 
receptor could be of therapeutic interest. Recently, fenobam, an mGlu5 NAM also known for 
its anxiolytic properties, entered phase II clinical studies, which so far have demonstrated 
potential therapeutic benefits on Fragile X symptoms (Berry-Kravis et al., 2009). 
 
Table 1. mGlu receptor ligands currently undergoing clinical trials. Sources: 
ClinicalTrials.gov and EvaluatePharma.com. * - Trial discontinued. 
mGlu2 and mGlu3 receptors are a major target for the treatment of anxiety and 
schizophrenia (Conn and Jones, 2009; Conn et al., 2009b). As a result, the activation of these 
receptors has been exploited for the treatment of said diseases in several clinical studies. 
Non-selective mGlu2/mGlu3 agonists have reached phase II clinical studies for the treatment 
of generalised anxiety disorders, but the trial was terminated due to risks of seizure 
observed in animals (Dunayevich et al., 2008). Allosteric ligands represent an alternative to 
the use of orthosteric ligands, since they do not interfere with the spatiotemporal profile of 
the endogenous ligand; therefore they are more targeted and usually produce less 
deleterious side effects. Recently, a phase I study on anxiety was started by Ortho-McNeil-
Janssen Pharmaceuticals Inc. and Addex pharmaceuticals using ADX71149, an mGlu2 PAM, 
but the conclusions remain known. Altered glutamatergic neurotransmission is also linked 
in part to schizophrenia and through a phase II study by Eli Lilly, the improvement of 
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symptoms of schizophrenia with an mGlu2/mGlu3 agonist was similar to that demonstrated 
with olanzapine, a common antipsychotic drug; this drug was also tolerated by patients 
(Patil et al., 2007).  
Preclinical studies strongly suggest that Group III mGlu receptors may play a vital role in 
the symptomatic control of Parkinson's disease. In particular, increasing mGlu4 activity 
within the basal ganglia appears to be an interesting approach to reduce akinetic symptoms 
associated with Parkinson's disease (Beurrier et al., 2009; Lopez et al., 2007). However, to our 
knowledge, none of these compounds have reached phase I clinical trials. 
3. Metabotropic GABA receptors 
3.1 Structure/function of GABAB receptors 
The metabotropic GABA (GABAB) receptor is the only known GPCR that is responsive to 
GABA. Architecturally, it is not composed in the same manner as many other Class C 
GPCRs. Specifically, it consists of a ligand binding GB1 subunit and a G protein coupling 
GB2 subunit (Galvez et al., 2001; Kaupmann et al., 1998; Margeta-Mitrovic et al., 2001; White 
et al., 1998); each subunit consisting of a VFT and 7TM domains, but converse to mGlu 
receptors they lack a CRD (refer to Figure 2 for schematic overview). The two subunits are 
not covalently associated, but do interact via a coiled-coil domain in their C-terminal tails, 
which provides a solid hydrophobic interaction to maintain the integrity of the dimer 
(Kammerer et al., 1999). Through the use of circular dichroism spectroscopy the authors 
proposed a region in the C-terminal domains of GB1 and GB2 of approximately 30 amino 
acids, composed of roughly 5-7 heptads.  
Discerning the number of ligands that bind to any one dimer at any one moment is often 
difficult, especially if there is the possibility for receptors to form higher-order oligomers. It 
has been shown that in class C heterodimers a single subunit was responsible for the 
binding of the endogenous ligand, in this case GB1 in the GABAB receptor (Kniazeff et al., 
2002). This suggests that a single agonist molecule is sufficient to fully activate 
heterodimeric receptors, but does not discount multiple binding sites on the same protomer. 
However, nearly nothing is known of the conformational movement of the GB2 subunit, 
making it nearly impossible to distinguish between the conformational rearrangement and 
functional responses of Aco and Acc combinations. The only insights come from the GABAB 
receptor, whereby the introduction of several large residues, such as tryptophan in the 
crevice of GB2 VFT leads to a decrease in G protein-mediated functional responses (Kniazeff 
et al., 2002). 
It has always been questioned whether GPCRs remain in simple monomeric and dimeric 
forms or whether they self-associate into higher-order oligomers and, if so, what are the 
molecular determinants of these interactions. Recently, it has been demonstrated that 
GABAB are indeed capable of forming tetrameric complexes, which interact via their GB1 
subunits (Comps-Agrar et al., 2011; Maurel et al., 2008). By employing the use of a binding-
null GB1 subunit Comps-Agrar et al., (2011) demonstrated that GABAB receptor tetramers 
could be disrupted and that the resultant complexes are capable of binding approximately 
twice as much radioligand compared to the wild-type; in addition to increasing the apparent 
Emax in functional tests. The synthesis of this study was that GABAB receptors that are 
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associated into a tetrameric assembly have reduced binding capacity and functional 
capability compared to GABAB receptors in dimeric form. Comps-Agrar et al., (2011) 
attempted to more precisely examine the structural determinants of the molecular 
construction of the GABAB receptor tetramer. They resolved that an important interaction 
between the VFTs of the GB1 subunits occurs, and then experimentally demonstrated the 
disruption of this interaction through mutation and insertion of an N-glycosylation site 
(G380N) increases the apparent Bmax of fluorescent ligand binding and maximal function 
effect in intracellular calcium mobilisation assays. It is noteworthy that this study 
demonstrated that there is tetramerisation of GB1A subunit-containing GABAB receptors, but 
not GB1B subunit-containing receptors.  
Stimulation of GABAB receptors results in the activation and dissociation of Gi/o family G 
proteins, which in turn inhibit the function adeylyl cyclase thereby decreasing intracellular 
cAMP levels; activate Kir3 channels and inhibit Cav2 channels (Dunlap and Fischbach, 1981; 
Leaney and Tinker, 2000; Nishikawa et al., 1997). One of the major actions of GABAB 
receptor activation is the opening of Kir3 channels, where the increase in K+ permeability 
through these channels hyperpolarises the cell thereby inhibiting the propagation of action 
potentials (Dascal, 1997; Misgeld et al., 1995).  
Many GPCRs undergo rapid receptor phosphorylation and subsequent sequestration from 
the cell surface, commonly in an arrestin-dependent manner, followed by the recruitment of 
scaffolding proteins and by clathrin-mediated endocytosis (Shenoy and Lefkowitz, 2005). 
One interesting feature that is dissimilar to many GPCRs and is the subject of much debate 
is that GABAB receptors do not appear to undergo activation-dependent phosphorylation 
and internalisation. Indeed, it has been reported that these receptors are not phosphorylated 
by the canonical G protein-coupled receptor kinases (GRKs), yet are desensitised by GRK4 
in the absence of any apparent phosphorylation (Perroy et al., 2003). It has been 
demonstrated in chick neurons that upon activation, GABAB receptors form a complex with 
Cav channels and arrestins, then are consequently internalised as a mechanism of rapid 
desensitisation of GABAB receptor signalling (Puckerin et al., 2006). This however, is 
conflicting with evidence provided by Fairfax et al., (2004) whereby GABAB receptors did 
not associate with arrestins and, indeed, the cAMP-dependent kinase- (PKA) mediated 
phosphorylation of the GABAB receptor at position Ser892 on the GB2 subunit increases its 
cell-surface stability; rather than impeding its cellular function. It would appear in these 
cases that the phosphorylation state and the subsequent events may very well be cell type 
specific, which may be yet another degree of complexity for texturing GABAB receptor-
mediated signalling. Interestingly, despite the lack of consistent evidence that GABAB 
receptors are phosphorylated as a consequence of receptor activation, there is an 
accumulating body of evidence that these receptors are phosphorylated mostly by second-
messenger kinases. For example, protein kinase C (PKC) has been described to 
phosphorylate the GB1 subunit GABAB receptors after the dissociation of the chaprone 
protein, N-ethylmaleimide-sensitive fusion (NSF) protein, in Chinese hamster ovary (CHO) 
cells (Pontier et al., 2006). More recently, there have been new developments on how GABAB 
receptors are phosphorylated and dephosphorylated in neurons. Recent evidence suggests 
that NMDA receptors can also act as regulators of GABAB receptor function, such that 
NMDA receptor activation, via calcium/calmodulin-dependent protein kinase, 
phosphorylates the GB1 subunit at position Ser867, resulting in rapid receptor 
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internalisation from dendritic spines and shafts in the hippocampus (Guetg et al., 2010). 
Similarly, prolonged NMDA receptor activation results in the rapid phosphorylation of 
Ser783 on GB2 in an 5' adenosine-monophosphate-dependent protein kinase- (AMPK) 
dependent manner (Terunuma et al., 2010). The rapid phosphorylation by AMPK altered the 
endocytic sorting pathway from receptor recycling to endosomal degradation, Ser783 was 
then slowly dephosphorylated by protein phosphatase 2A, returning the system back to its 
receptor recycling processes. Although the modes of which GABAB receptors are 
phosphorylated and there consequences are not entirely clear, recently there has been a 
great deal of progress made in understanding how GABAB receptor phosphorylation is 
affected by distinct signalling systems and their consequences on receptor function.  
3.2 Localisation and physiology of GABAB receptors 
The GABAB receptor is extensively expressed throughout the central nervous system, 
specifically, hippocampus, cortex, thalamus and cerebellum (Bettler and Tiao, 2006; Billinton 
et al., 1999); and in parts of the peripheral nervous system. They are located both pre- and 
post-synaptically where they mediate activity of Cav and Kir3 channels, respectively (Dutar 
and Nicoll, 1988; Lopez-Bendito et al., 2004; Luscher et al., 1997). Presynaptic GABAB 
receptors can be found at both homo- and hetero-autoreceptors on GABA and, for example, 
glutamate nerve terminals, respectively (Thompson et al., 1993). Activation of these 
receptors leads to a hyperpolarisation of the nerve terminal thereby inhibiting further 
neurotransmitter release. Postsynaptically, GABAB receptors have been demonstrated to 
mediate slow inhibitory postsynaptic potentials (IPSPs) through the operation of Kir3 
channels. It is noteworthy that in the human brain, there are two major isoforms of the 
GABAB receptors, those that contain a GB1A subunits, and those that possess GB1B subunits, 
notwithstanding there is no apparent difference in pharmacology or physiology between the 
two receptors in heterologous cell systems (Ulrich and Bettler, 2007). Despite a lack of 
obvious differences in function and pharmacology, there is indeed a differential expression 
pattern, such that GB1A and GB1B are both expressed on GABAergic nerve terminals, yet 
only GB1A subunits are expressed on glutamatergic synaptic terminals (Kulik et al., 2003). By 
using different sets of complementary approaches, the authors showed that GB1A-containing 
heterodimers mainly control presynaptic release of glutamate, whereas receptors possessing 
GB1B subunits predominantly mediate post-synaptic inhibition.   
3.3 GABAB receptor pharmacology and clinical relevance 
Similar to mGlu receptors, GABAB receptors have two main ligand-binding domains, the 
orthosteric ligand-binding pocket located within the VFT of GB1; and the allosteric ligand-
binding domain, which is within the 7TM region, most likely within the 7TM bundle. There 
are surprisingly few GABAB receptor full agonists aside from GABA itself and the well-
known baclofen (refer to Figure 5). There are some other agonists such as CGP27492, the 
tritiated form of which replaced [3H]-baclofen as the radioligand agonist of choice, but was 
surrounded by controversy when it failed to reproduce the same physiological effects in 
some key assays (Froestl et al., 1995). A number of GABAB receptor partial agonists have 
been identified, the most famous of which is the endogenous metabolite of GABA,-
hydroxybutyric acid (GHB), synthesised from GABA transaminase and semialdehyde 
reductase. Other partial agonists include CGP44532 and CGP35024, the latter is also a 
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GABAC receptor antagonist (Chebib et al., 1997). The number of antagonists is much greater 
than that of agonists, among these ligands there are the baclofen derivatives, saclofen and 2-
OH saclofen; CGP54626, the most common of the antagonists; and CGP71872; the former 
two possessing high micromolar affinity, whilst the latter two exhibit low nanomolar 
affinity (Kaupmann et al., 1997).  
 
Fig. 5. Structural similarities across common GABAB receptor agonists. 
As with many Class C GPCRs, there exist a number of allosteric modulators available for the 
GABAB receptor, yet all known modulators are PAMs, with no known NAMs, to date. Some 
PAMs of the GABAB receptor are CGP7930, GS39783 and the more recent, rac-BHFF 
(Malherbe et al., 2008; Pin and Prezeau, 2007)(Figure 6). These PAMs increase orthosteric 
agonist potency and maximal response in a system-dependent manner, whilst possessing 
partial agonism in their own right. Given that many PAMs will most often on activate their 
target receptor when the endogenous or orthosteric ligand is present, they offer an ideal 
approach for drug discovery given they maintain region-dependent transmission patterns, 
therefore theoretically limiting off-target effects and side effect profile. 
 
Fig. 6. Two of the best characterised positive allosteric modulators at the GABAB receptor. 
3.3.1 Addiction and GABAB receptors 
Today, there are two GABAB receptor ligands on the market, both agonist, but both treat 
largely different disorders. Baclofen, originally developed to treat epilepsy in the 1920s, was 
largely unsuccessful for the treatment of epileptic symptoms, but its potential was realised 
outside of epileptic patients. Among the more common uses for baclofen is the treatment of 
addiction of abusive substances. Specifically, alcohol dependence has received much 
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attention with regard to GABAB receptors, such that baclofen administration in open-label 
trials reduced the number of heavy-drinking days and increased the number of abstinence 
days, in addiction to decreasing biological markers such as alanine aminotranferase and 
gamma glutamyl-transpeptidase, in some patients (Addolorato et al., 2000; Flannery et al., 
2004). Baclofen was not only useful for the management of alcohol addiction, but may also 
be employed as a strategy against withdrawal and relapse (Addolorato et al., 2006). When 
compared with treatment of diazepam, baclofen was only slightly less efficient at reducing 
the symptoms of alcohol withdrawal, such as sweating, anxiety and agitation; however this 
suggests baclofen may be a useful treatment for alcohol withdrawal in patients that abuse 
other substances, for example, benzodiazepines.  
Baclofen has also been investigated for its effects on relieving addiction to cocaine. In one 
study, users of freebase or crack cocaine who self-administered through inhalation of the 
drug (Haney et al., 2006). Users who were either treated with methadone or not were given 
varying doses of baclofen and subsequently were asked to choose to take either the available 
dose of cocaine or five dollar merchandise voucher. The group who were administered 
60mg of baclofen and non-methadone treated demonstrated a decrease in the craving for the 
low dose of cocaine (12mg), whilst there was no change in the methadone-treated group. 
Interestingly, baclofen also decreased the effect of cocaine on heart rate, however the 
personal evaluation of the 'high' remained unchanged. These results suggest that in some 
specific cases that baclofen would have a positive effect on addiction, however these 
situations are also often confounded by psychological dependence and are by and large 
heavily dictated by the patient. 
3.3.2 GHB and current therapeutic indications 
As previously mentioned, GHB is a minor metabolite of GABA; however in the 1960s GHB 
was first developed as a therapeutic as a CNS depressor (Laborit et al., 1960). At the time, it 
was also used as an adjuvant for anesthetics and is still used in some countries as an 
intravenous anesthesia (Kleinschmidt et al., 1997). Nowadays, the therapeutic indications for 
GHB are cataplexy and excessive daytime sleepiness associated with sleep disorder 
narcolepsy. Narcolepsy is the condition characterised by interrupted nighttime sleep and 
excessive daytime sleep, in addition to this, approximately 70% of narcoleptics suffer from 
cataplexy, which is a sudden loss of muscle tone. The evidence of clinical efficacy of GHB is 
largely empirical through a number of studies on narcoleptic patients, daily doses of GHB 
was able to reduce the number of nocturnal sleep/awake transitions, cataplexy episodes and 
the frequency between wakefulness and REM sleep during the daytime (Pardi and Black, 
2006; Scrima et al., 1990). Despite clinical evidence supporting the therapeutic benefits of 
GHB for these conditions, there is still much debate over the molecular mechanism of action 
of GHB. There is known to be at least two GHB-binding sites, a high-affinity site on an 
unidentified protein; and a low-affinity site, which is at the GABAB receptor (Kaupmann et 
al., 2003). However, there is evidence that the effects of GHB on stabilising patterns of 
somnolence are due to the subsequent actions at the GABAB receptor. Recently, Vienne et al., 
(2010) provided evidence that the effects on somnolence and circadian sleep organisation 
are dependent on GABAB receptors, whereby GHB and baclofen stabilised sleep/wake 
regulation in wild-type mice; these effects were lost in both GB1-/- and GB2-/- mice. This 
study suggests that the therapeutic benefits of GHB in narcoleptic patients may be mostly 
due to GHB-mediated activation of GABAB receptors.   
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3.3.3 GABAB receptors in pain 
The importance of GABAB receptors in nociceptive processing was well documented in the 
early 90's in a series of preclinical studies in which the GABAB receptor agonist, baclofen, 
exhibited antinociceptive properties in models of acute (Malcangio et al., 1991) and chronic 
pain (Dirig and Yaksh, 1995; Smith et al., 1994). These effects are likely mediated by spinal 
and supraspinal GABAB receptors; where the supraspinal effects appear to reflect 
depression of ascending adrenergic and dopaminergic input to the brainstem, and 
facilitation of descending noradrenergic input to the spinal cord dorsal horn (Sawynok, 
1984). Baclofen-induced antinociception at spinal cord level is attributed, at least partly, to 
the activation of presynaptic GABAB receptors localised on the nerve terminals of 
peptidergic primary afferents fibers (Price et al., 1984). In the substantia gelatinosa of the 
spinal cord, baclofen exhibits a greater effect on C-fibers than Aδ-fiber-evoked glutamate 
release, suggesting a preferential GABAB expression in C fibers afferent terminals (Ataka et 
al., 2000). Furthermore, baclofen inhibits electrically-evoked release of calcitonin gene-
related peptide (CGRP) (Malcangio and Bowery, 1995) and substance P (Marvizon et al., 
1999) from rat spinal cord slices. The decrease of dorsal horn neurons excitability and the 
regulation of intrinsic neuronal properties suggest additional postsynaptic sites for the 
action of baclofen on pain (Derjean et al., 2003; Kangrga et al., 1991). Taken together, the 
effects of activation of GABAB receptors on the inhibition of pain signalling suggest that it is 
a tractable target for combating neuropathic and potentially other types of pain.  
4. Concluding remarks 
The treatment of neurological disorders is perhaps one of the most difficult tasks in modern 
day medicine; the multi-factorial nature of disease and the availability of appropriate 
therapeutics continually hamper the drug discovery process. The initial step in surmounting 
these obstacles is the validation of a target, which is perpetually being revised and, has now 
furnished two invaluable targets in the mGlu and GABAB receptors. Both receptors, which 
present the major excitatory and inhibitory GPCR conduits, could be targeted for the 
treatment of a myriad of central and peripheral disorders. To better understand the function 
and physiology of these receptors it is paramount that we elucidate molecular mechanisms 
of receptor activation and ligand binding. There exists a large body of work the 
pharmacology of mGlu and GABAB receptors, yet we are only now scratching the surface, as 
recently there has been an influx on novel receptor-selective pharmacophores, especially for 
mGlu receptors. With a better pharmacological armamentarium we will be better equipped 
to delineate (patho)physiological phenomena as we progress development of better 
therapeutics.   
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